ChainGen Bio

ChainGen Bio specializes in drug conjugation and delivery technologies. As a pioneer in China, it has developed antibody-small nucleic acid conjugate drugs, filling the gap in extrahepatic delivery of nucleic acid therapeutics and bringing hope to patients with neuromuscular diseases who have long suffered from limited treatment options. Furthermore, ChainGen Bio’s Brainferry platform, a brain-penetrating peptide technology, holds the potential to help macromolecular drugs, including small nucleic acids, cross the blood-brain barrier, thereby revolutionizing the treatment of a broader range of neurodegenerative diseases such as Alzheimer’s disease and Parkinson’s disease.